Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Identifying Novel and Causual Cardiometabolic Biomarkers with Mendelian Randomization
EF 2020-21
Résumé
Millions of Canadians are affected by cardiometabolic diseases which include coronary artery disease, stroke, diabetes, heart failure, and chronic kidney disease. Studies aimed at uncovering novel and causal cardiometabolic biomarkers can improve patient management and outcomes of these diseases. This is because biomarkers are measurable factors (i.e. plasma proteins, autoantibodies, and metabolites) that correlate with the severity or progress of specific diseases. Their utility extends to early clinical diagnosis, disease prevention, and response to drug treatment. There is room for improvement in current biomarker detection strategies and platforms in part due to the scarcity of studies that screen for biomarkers and the inability to distinguish markers of disease from mediators of disease. We propose to overcome these challenges by implementing an innovative design to comprehensively screen for novel biomarkers that (1) predict a wide range of cardio-metabolic diseases, and (2) are causally involved in the pathophysiology of diseases so they can be targets for interventions. We will use our experience in Mendelian Randomization, a protocol based on independent genetic variant segregation akin to a natural ""Randomized Control Trial,"" to identify blood mediators of cardio-metabolic disease through a systematic testing of 1196 plasma proteins in biological samples already collected as part of the Prospective Urban and Rural Epidemiological PURE study (N=12,000 participants). Identifying novel causal mediators of disease is urgently needed to improve risk stratification and therapeutic options. Discovering biomarkers that not only predict risk but are also causal mediators would be transformative in their ability to identify patients at risk and to monitor treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449339
Name
Di Scipio Matteo
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying Novel and Causual Cardiometabolic Biomarkers with Mendelian Randomization
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biobank; Bioinformatics; Biomarkers; Cardiometabolic; Causal Mediators; Genomics; Linear Models; Mendelian Randomization; Molecular Epidemiology; Population Health
Abstract
Millions of Canadians are affected by cardiometabolic diseases which include coronary artery disease, stroke, diabetes, heart failure, and chronic kidney disease. Studies aimed at uncovering novel and causal cardiometabolic biomarkers can improve patient management and outcomes of these diseases. This is because biomarkers are measurable factors (i.e. plasma proteins, autoantibodies, and metabolites) that correlate with the severity or progress of specific diseases. Their utility extends to early clinical diagnosis, disease prevention, and response to drug treatment. There is room for improvement in current biomarker detection strategies and platforms in part due to the scarcity of studies that screen for biomarkers and the inability to distinguish markers of disease from mediators of disease. We propose to overcome these challenges by implementing an innovative design to comprehensively screen for novel biomarkers that (1) predict a wide range of cardio-metabolic diseases, and (2) are causally involved in the pathophysiology of diseases so they can be targets for interventions. We will use our experience in Mendelian Randomization, a protocol based on independent genetic variant segregation akin to a natural ""Randomized Control Trial,"" to identify blood mediators of cardio-metabolic disease through a systematic testing of 1196 plasma proteins in biological samples already collected as part of the Prospective Urban and Rural Epidemiological PURE study (N=12,000 participants). Identifying novel causal mediators of disease is urgently needed to improve risk stratification and therapeutic options. Discovering biomarkers that not only predict risk but are also causal mediators would be transformative in their ability to identify patients at risk and to monitor treatment.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Di Scipio, Matteo
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~